Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gadoxetate disodium

Drug Profile

Gadoxetate disodium

Alternative Names: EOB Primovist; Eovist; gadolinium EOB DTPA; gadoxetic acid; Gd-EOB-DTPA; Primovist; ZK 139834

Latest Information Update: 18 Jul 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Massachusetts General Hospital
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Acetic acids; Gadolinium-containing contrast agents; Organometallic compounds; Polyamines; Small molecules
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Apr 2017 Discontinued - Phase-III for Liver disorders (Diagnosis, In infants) in USA (IV), because not listed on Bayer pipeline, April 2017
  • 01 Feb 2015 Phase-III clinical trials in Liver disorders (Diagnosis, In infants) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top